Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLR1A | O95602 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381985 | 1.00 | L3MBTL1 (0.41) | L3MBTL1OPRM1OPRL1NPSR1OPRD1 | |
| SCHEMBL2380430 | 0.78 | CHRM3 (0.43) | L3MBTL1OPRM1OPRL1HTTF2 | |
| SCHEMBL2380933 | 0.78 | HTT (0.41) | L3MBTL1OPRM1OPRL1HTTF2 | |
| SCHEMBL2380597 | 0.75 | PARP1 (0.47) | OPRM1OPRL1HTTMEN1LMNA | |
| SCHEMBL2381083 | 0.75 | PARP1 (0.47) | OPRM1OPRL1HTTMEN1LMNA | |
| SCHEMBL2311285 | 0.75 | ALDH1A1 (0.44) | HTTMEN1KMT2A | |
| SCHEMBL2543128 | 0.74 | OPRM1 (0.40) | L3MBTL1OPRM1OPRL1HTTMEN1 | |
| SCHEMBL2381415 | 0.72 | NPC1L1 (0.45) | OPRM1OPRL1HTTMEN1LMNA | |
| SCHEMBL2543025 | 0.72 | HPGD (0.53) | NPSR1HTTMEN1LMNAKMT2A | |
| SCHEMBL2540212 | 0.71 | SLC6A9 (0.40) | OPRM1OPRL1NPSR1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | L3MBTL1 3228/4885OPRM1 593/4885OPRL1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.